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1. INTRODUCTION {#mgg3527-sec-0005}
===============

Lysosomal storage diseases (LSD) affect approximately 1 in 5,000--8,000 worldwide. Currently, mutations in over 50 genes have been reported to disrupt the lysosomal metabolism, leading to a wide spectrum of disease phenotypes including neuropathological effects, musculoskeletal abnormalities, dysmorphia, hepatosplenomegaly, and the occurrence of seizures. For any specific LSD, these multiorgan phenotypes can be present in a varying degree and show significant overlaps across different LSDs. And although most LSDs manifest themselves during early childhood, certain diseases have a genetically specific late‐onset form (e.g., Pompe) or display only more severe effects later in life (e.g., Fabry). Given these challenges, the path to a diagnosis for an LSD in an affected patient can be long and is often unsuccessful. Current diagnostic workflows are predominantly sequential in nature, implying only one test (e.g., urine or biochemical analysis) is initiated depending on the suspicion of the disease.

The use of next‐generation sequencing (NGS) in the clinic during recent years has resulted in a significant increase in diagnostic yield both through a targeted approach with gene panels or untargeted strategies based on whole‐exome sequencing. Here, we propose the incorporation of gene panel testing in the LSD diagnostic workflow. For this purpose, we developed a panel comprising 51 genes which are interrogated based on probe capturing. We investigated 150 patients with a clinical suspicion of an LSD and evaluated this approach compared to classical sequential biochemical testing based on fluorimetric methodologies.

2. MATERIALS AND METHODS {#mgg3527-sec-0006}
========================

2.1. Patient selection {#mgg3527-sec-0007}
----------------------

The inclusion procedure of the patients in our study was approved by the ethical commission of UZBrussel. During a follow‐up study of 18 months, samples of patients with a suspicion of a lysosomal storage disease were collected and analyzed in our standard diagnostic workflow. In total, the cohort consisted of 150 samples. All pathogenic or potentially pathogenic mutations discovered by the gene panel analysis were confirmed by means of classical Sanger sequencing. Whenever possible, segregation analysis was performed on the patients parents using Sanger sequencing.

2.2. Gene panel analysis {#mgg3527-sec-0008}
------------------------

Genomic DNA was isolated from blood specimens using the Chemagen DNA kit (PerkinElmer, Shelton, CT) and quantified on a NanoDrop spectrophotometer (ThermoFisher Scientific, Charlotte, NC). Subsequently, the DNA was fragmented with a Covaris ultrasonicator instrument (Woburn, MA). Gene coding regions, as well as the flanking intronic sequences, were captured using SeqCap target enrichment probes (Roche, Basel, Switzerland) according to the manufacturer\'s protocol. The libraries were paired‐end sequenced (2 × 125 bp) on a HiSeq 1500 machine (Illumina, San Diego, Ca). A minimum coverage of 30× was calculated. FastQ files were analyzed with the SeqNext software package (JSI Medical, Ettenheim, Germany).

2.3. Analysis of genomic deletions {#mgg3527-sec-0009}
----------------------------------

Verification of the common 65 kb deletion in the *CTNS* gene was performed according to the methods described by Forestier et al. ([1999](#mgg3527-bib-0012){ref-type="ref"}) and Anikster et al. ([1999](#mgg3527-bib-0002){ref-type="ref"}). Detection of the *CLN3* deletion was carried out based on the methodology of Taschner, Vos, and Breuning ([1997](#mgg3527-bib-0029){ref-type="ref"}).

2.4. Biochemical confirmation {#mgg3527-sec-0010}
-----------------------------

The biochemical confirmation was performed both in external accredited laboratories or in‐house. In‐house confirmation was done for IDUA (Anson, Bielicki, & Hopwood, [1992](#mgg3527-bib-0003){ref-type="ref"}; Clements, Muller, & Hopwood, [1985](#mgg3527-bib-0007){ref-type="ref"}), GAA (Beratis, LaBadie, & Hirschhorn, [1978](#mgg3527-bib-0004){ref-type="ref"}) and GBA (Beutler & Kuhl, [1970](#mgg3527-bib-0005){ref-type="ref"}). Briefly, for IDUA and GBA activity measurements, peripheral blood leukocytes were used and were extracted by adding 2 ml of a 2% dextran solution to 5 ml of blood sample. After 30 min, the supernatant was collected and centrifuged for 6 min at 750 *g*. Subsequently, the cell pellet was washed three times with a 3.6% NaCl solution. Lysis of the cells occurred by resuspending the pellet in cold 3.6% NaCl solution and freeze/thawing the suspension at −80°C. For GAA activity measurement, the same procedure was followed, but skin fibroblasts were used as starting material. Protein content was determined with a standard Lowry assay. For the IDUA activity measurement, the 4MU‐α‐L‐iduronide cyclohexylammonium substrate was used. For GAA activity, the 4MU‐α‐D‐glucopyranoside substrate was used. Measurements were performed under pH4 and pH6 conditions. For GBA, the 4MU‐β‐D‐glucopyranoside substrate was used.

3. RESULTS {#mgg3527-sec-0011}
==========

3.1. Gene selection and panel coverage {#mgg3527-sec-0012}
--------------------------------------

The composition of our gene panel is shown in Table [1](#mgg3527-tbl-0001){ref-type="table"}. All 51 tested genes were reported as direct cause of an LSD when mutated in both alleles. For all genes, all exons are covered, so no specific potential hotspots are missed. We did not include genes where a direct connection between mutation and lysosomal storage disease was not thoroughly established. The panel is therefore well suited for diagnostic testing in patients with high a priori probability of LSD based on the clinical phenotype and is not designed as an untargeted screening‐oriented assay.

###### 

Overview of the genes which are investigated with the LSD gene panel

  Name disease                           Enzyme/protein                                                   Gene        Omim              RefSeq
  -------------------------------------- ---------------------------------------------------------------- ----------- ----------------- ----------------------------------
  alpha‐fucosidase                       alpha‐L‐fucosidase                                               *FUCA1*     230,000           [NM_000147.4](NM_000147.4)
  alpha‐mannosidase                      alpha‐D‐mannosidase                                              *MAN2B1*    248,500           [NM_000528.3](NM_000528.3)
  Aspartylglucosaminuria                 aspartylglucosaminidase                                          *AGA*       208,400           [NM_001171988.1](NM_001171988.1)
  beta‐mannosidase                       beta‐D‐mannosidase                                               *MANBA*     248,510           [NM_005908.3](NM_005908.3)
  chitotriosidase                        chitotriosidase                                                  *CHIT1*     600,031           [NM_003465.2](NM_003465.2)
  CLN1                                   palmitoyl protein thioesterase I                                 *PPT1*      256,730           [NM_000310.3](NM_000310.3)
  CLN10                                  cathepsin D                                                      *CTSD*      610,127           [NM_001909.4](NM_001909.4)
  CLN2                                   tripeptidyl peptidase I                                          *TPP1*      204,500           [NM_000391.3](NM_000391.3)
  CLN3                                   ceroid‐lipofuscinosis, neuronal 3                                *CLN3*      204,200           [NM_001042432.1](NM_001042432.1)
  CLN5                                   ceroid‐lipofuscinosis, neuronal 5                                *CLN5*      256,731           [NM_006493.3](NM_006493.3)
  CLN6                                   ceroid‐lipofuscinosis, neuronal 6                                *CLN6*      601,780           [NM_017882.2](NM_017882.2)
  CLN7                                   Major facilitator superfamily domain containing 8                *MFSD8*     610,951           [NM_152778.2](NM_152778.2)
  CLN8                                   ceroid‐lipofuscinosis, neuronal 8                                *CLN8*      600,143           [NM_018941.3](NM_018941.3)
  Cystinosis                             cystinosin (cystine transporter)                                 *CTNS*      606,272           [NM_004937.2](NM_004937.2)
  Danon disease                          Lysosome‐associated membrane protein 2                           *LAMP2*     300,257           [NM_001122606.1](NM_001122606.1)
  Fabry disease                          alpha‐galactosidase                                              *GLA*       300,644           [NM_000169.2](NM_000169.2)
  Farber lipogranulomatosis              acid ceramidase                                                  *ASAH1*     228,000           [NM_177924.4](NM_177924.4)
  Galactosialidosis                      cathepsin A                                                      *CTSA*      256,540           [NM_000308.3](NM_000308.3)
  Gaucher disease                        beta‐glucosidase                                                 *GBA*       230,800           [NM_001005742.2](NM_001005742.2)
  GM1‐gangliosidosis                     beta‐galactosidase                                               *GLB1*      230,500           [NM_000404.3](NM_000404.3)
  GM2‐gangliodidosis AB                  GM2 activator                                                    *GM2A*      613,109           [NM_001167607.1](NM_001167607.1)
  GM2‐gangliosidosis/Sandhoff            N‐acetyl‐beta‐hexosaminidase A+B                                 *HEXB*      268,800           [NM_000521.3](NM_000521.3)
  GM2‐gangliosidosis/Tay‐Sachs           N‐acetyl‐beta‐hexosaminidase A                                   *HEXA*      272,800           [NM_000520.5](NM_000520.5)
  Krabbe disease                         galactocerebrosidase                                             *GALC*      245,200           [NM_000153.3](NM_000153.3)
  Metachromatic leukodystrophy           arylsulfatase A                                                  *ARSA*      250,100           [NM_000487.5](NM_000487.5)
  MPS1/Hurler syndrome                   alpha‐L‐iduronidase                                              *IDUA*      252,800           [NM_000203.5](NM_000203.5)
  MPS2/Hunter syndrome                   iduronate 2‐sulfatase                                            *IDS*       309,900           [NM_001166550.3](NM_001166550.3)
  MPS3A/Sanfilippo syndrome A            N‐sulfoglucosamine sulfohydrolase                                *SGSH*      252,900           [NM_000199.4](NM_000199.4)
  MPS3B/Sanfilippo syndrome B            N‐acetylglucosaminidase                                          *NAGLU*     252,920           [NM_000263.3](NM_000263.3)
  MPS3C/Sanfilippo syndrome C            heparan‐alpha‐glucosaminide N‐acetyltransferase                  *HGSNAT*    252,930           [NM_152419.2](NM_152419.2)
  MPS3D/Sanfilippo syndrome D            glucosamine (N‐acetyl)‐6‐sulfatase                               *GNS*       252,940           [NM_002076.3](NM_002076.3)
  MPS4A/Morquio syndrome A               galactosamine (N‐acetyl)‐6sulfate sulfatase                      *GALNS*     253,000           [NM_000512.4](NM_000512.4)
  MPS4B/Morquio syndrome B               Beta‐galactosidase‐1                                             *GLB1*      253,010           [NM_000404.3](NM_000404.3)
  MPS6/Maroteaux--Lamy syndrome          arylsulfatase B                                                  *ARSB*      253,200           [NM_000046.4](NM_000046.4)
  MPS7/Sly syndrome                      beta‐glucuronidase                                               *GUSB*      253,220           [NM_001293105.1](NM_001293105.1)
  MPS9                                   Hyaluronidase‐1                                                  *HYAL1*     607,071           [NM_153281.1](NM_153281.1)
  Mucolipidose 1                         neuraminidase                                                    *NEU1*      256,550           [NM_000434.3](NM_000434.3)
  Mucolipidosis II alpha/beta or III     N‐acethylglucosamine‐1‐phosphotransferase, alpha/beta subunits   *GNPTAB*    252,500/255,600   [NM_024312.4](NM_024312.4)
  Mucolipidosis III gamma                N‐acethylglucosamine‐1‐phosphotransferase, gamma subunit         *GNPTG*     255,605           [NM_032520.4](NM_032520.4)
  Multiple sulfatase deficiency          sulfatase modifying factor 1                                     *SUMF1*     272,200           [NM_182760.3](NM_182760.3)
  Niemann--Pick A&B                      sphinogmyelinase                                                 *SMPD1*     257,200           [NM_001007593.2](NM_001007593.2)
  Niemann--Pick C1                       NPC1                                                             *NPC1*      257,220           [NM_000271.4](NM_000271.4)
  Niemann--Pick C2                       NPC2                                                             *NPC2*      601,015           [NM_001363688.1](NM_001363688.1)
  Papillon--Lefevre syndrome             cathepsin C                                                      *CTSC*      602,365           [NM_001814.5](NM_001814.5)
  Pompe disease                          alpha‐glucosidase                                                *GAA*       232,300           [NM_001079804.2](NM_001079804.2)
  Prosaposin deficiency                  prosaposin                                                       *PSAP*      176,801           [NM_002778.3](NM_002778.3)
  Pycnodysostosis                        cathepsin K                                                      *CTSK*      265,800           [NM_000396.3](NM_000396.3)
  Salla disease, sialuria                solute carrier family 17 (sodium phosphate cotransporter)        *SLC17A5*   604,369           [NM_012434.4](NM_012434.4)
  Schindler disease                      Nac‐alpha‐D‐galactosaminidase                                    *NAGA*      609,241           [NM_000262.2](NM_000262.2)
  Steroid sulfatase                      arylsulfatase C                                                  *STS*       308,100           [NM_000351.5](NM_000351.5)
  Wolman disease, cholesteryl ester SD   acid lipase, cholesterol esterase                                *LIPA*      278,000           [NM_001127605.2](NM_001127605.2)
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We first assessed its overall analytical performance in terms of depth of coverage in test samples (*n* = 5) that were previously Sanger‐sequenced for LSD‐causing genes. All exons showed an average coverage above 30× (Figure [1](#mgg3527-fig-0001){ref-type="fig"}a). We also assessed the evenness of coverage within the individual exons (Figure [1](#mgg3527-fig-0001){ref-type="fig"}b): 79% (548 of 609) of exons were fully covered, with each individual base covered at least 30×. In only 2% (12 of 609) of exons coverage was suboptimal, with 15% or more bases not reaching 30× coverage. On the basis of this data, we conclude that our panel performs sufficiently for the implementation in the clinic.

![(a) Average coverage of the 609 exons in the LSD gene panel. For each exon, the average coverage was calculated by adding the read depth of each base divided by the total exon length. (b) Graphical overview of percentage of coverage per exon. For each exon, this was calculated by dividing the number of bases with a coverage above 30× by the total number of bases. Five hundred and forty‐eight of a total of 609 exons have a coverage of 100% (fully covered). For three exons, \<10% of their nucleotides are covered above 30×](MGG3-7-na-g001){#mgg3527-fig-0001}

3.2. Sample statistics and diagnostic rate {#mgg3527-sec-0013}
------------------------------------------

Over a period of 18 months, we analyzed 150 samples. As most LSDs present themselves during childhood or adolescence, most patients we analyzed were in this age group. A second important number of patients are in the age group of 30--45 years (Figure [2](#mgg3527-fig-0002){ref-type="fig"}a). Since children and adolescents are expected to present with a more severe phenotype than the late‐onset patients, we expected the diagnostic success rate to be higher in the younger patient population. Comparing the diagnostic success rate in both patient groups, however, revealed no large differences (Figure [2](#mgg3527-fig-0002){ref-type="fig"}b).

![(a) Age distribution of the patients who were tested with the LSD gene panel. (b) Age distribution of the patients in whom a diagnosis was found and where heterozygous mutations were found](MGG3-7-na-g002){#mgg3527-fig-0002}

An overview of the different mutations resulting in a confirmed or likely diagnosis is given in Table [2](#mgg3527-tbl-0002){ref-type="table"}. In total, we established a diagnosis in 22 of 150 cases, implying a diagnostic yield of 15%. In comparison, we obtained a yield of 4.58% with our previously 4MU‐based biochemical testing panel for 21 LSDs when looking over a period of 30 months (Table [2](#mgg3527-tbl-0002){ref-type="table"}). Interestingly, four of 22 diagnosed patients were carrier of disease alleles with a pathogenic deletion. For instance, in the *CTNS* and the *CLN3* gene, these deletions are common alleles. In the case of *CTNS*, the 57 kb deletion, comprising exon 1--10, is present in 76% percent of cystinosis patients (Forestier et al., [1999](#mgg3527-bib-0012){ref-type="ref"}). Likewise, for *CLN3,*the 1.02 kb deletion, spanning exon 7 and 8, is present in 73% of all alleles causing ceroid neuronal lipofuscinosis type 3 (Taschner et al., [1997](#mgg3527-bib-0029){ref-type="ref"}). These findings stress the need for detection of these deletions into the standard diagnostic LSD pipeline. These deletions cannot be readily detected with our NGS methodology and are detected through standard PCR amplification followed by determination of the amplicon size. Other LSDs where we perform additional deletion analysis are Krabbe and Pompe\'s disease.

###### 

Overview of the diagnostic rate of the enzymatic 4MU‐based testing over a period of 30 months. A diagnostic yield of 4.58% was obtained

  Disease                        Enzyme                                               Detected
  ------------------------------ ---------------------------------------------------- ----------
  Alpha mannosidosis             Alpha‐mannosidase B                                  1
  Fabry                          Alpha‐galactosidase                                  5
  Fucosidosis                    Fucosidase                                           1
  Gaucher                        Acid beta‐glucosidase                                4
  Hunter                         Iduronate‐2‐sulphatase                               4
  Hurler                         Alpha iduronidase                                    2
  Krabbe                         Galactocerebrosidase                                 1
  Marotaux‐Lamy                  Aryl sulphatase B                                    4
  Metachromatic leukodystrophy   Aryl sulphatase A                                    6
  Morquio A                      Galactosamine‐6‐sulphatase                           3
  Niemann--Pick A/B              Sphingomyelinase                                     1
  Pompe                          Acid alpha‐glucosidase                               7
  Sanfilippo A                   Alpha‐N‐sulfoglucosamine sulfohydrolase              2
  Sanfilippo B                   N‐acetyl‐D‐glucosaminidase                           3
  Sanfilippo C                   Acetyl‐CoA:Alpha‐glucosaminide N‐acetyltransferase   2
  Sialidosis I/II                Neuraminidase 1                                      1
  Tay‐Sachs                      Hexosaminidase A                                     2
                                 Sum                                                  49
                                 Total of performed analyses                          1,069
                                 Percentage                                           4.58%
  Not performed/detected                                                              
  Sanfilippo D                   N‐acetylglucosamine‐6‐sulfatase                      
  Sly disease                    Beta‐glucuronidase                                   
  GM1 gangliosidosis             Beta‐galactosidase                                   
  Schindler disease              alpha‐NAc‐galactosaminidase                          
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In addition, several patients were also found to be carriers of (likely) pathogenic mutations or a variant of uncertain clinical significance (VUS) in one of the LSD genes tested (Table [3](#mgg3527-tbl-0003){ref-type="table"}). This potentially implies that a large deletion could be responsible for the dysfunctionality of the other allele. However, in a diagnostic setting, investigating the potential role for deletions is only to be considered in case the clinical phenotype of the patient corresponds to the disease spectrum of the gene where a heterozygous mutation is detected. Furthermore, even if a second hit is not found, carrier status implies that the patient and family members can be counseled accordingly. In our study cohort, two patients were detected to be heterozygous for mutations in the *GBA* gene (Table [4](#mgg3527-tbl-0004){ref-type="table"}). Based on the clinical phenotype, a suspicion for Gaucher\'s disease could be excluded. However, the connection between heterozygous *GBA* mutations and the development of Parkinson Disease (PD) is starting to be uncovered (Li et al., [2014](#mgg3527-bib-0020){ref-type="ref"}; Schapira, [2015](#mgg3527-bib-0026){ref-type="ref"}). Therefore, detection of these mutations has important consequences toward a treatment or follow‐up before the clinical onset of PD of the patient and family members. In line with these findings, we have detected several patients as carrier of a pathogenic mutation in other LSD related genes as well (Tables [3](#mgg3527-tbl-0003){ref-type="table"} and [4](#mgg3527-tbl-0004){ref-type="table"}). For example, the heterozygous c.220C\>T mutation was detected in the *SGSH* gene causing mucopolysaccharidosis type 3A (Sanfilippo A). Although only one mutation was detected, the sample was biochemically tested and was found to be SGSH enzyme deficient. Thus, it is possible that the diagnostic yield estimate is higher than the 15% we report here.

###### 

Overview of the variants in patients in whom only one mutation in a specific gene could be detected

  Gene       Mutations             Protein            Effect                                 Literature
  ---------- --------------------- ------------------ -------------------------------------- -----------------------------------------------------------------------------------------------------
  *IDUA*     c.1205G\>A            p.Trp402\*         Pathogenic                             Scott, Litjens, Hopwood, and Morris ([1992](#mgg3527-bib-0027){ref-type="ref"})
  *GNPTG*    c.52+2T\>G            p.?                Splice effect (5/5 prediction tools)   NA
  *NPC2*     c.441+1G\>A           p.?                Pathogenic                             Staining
  *PPT1*     c.363‐4G\>A           p.?                Splice effect (0/5 prediction tools)   Kousi, Lehesjoki, and Mole ([2012](#mgg3527-bib-0018){ref-type="ref"})
  *TPP1*     c.509‐1G\>C           p.?                Splice effect (5/5 prediction tools)   Dy, Sims, and Friedman ([2015](#mgg3527-bib-0011){ref-type="ref"})
  *GBA*      c.1223C\>T            p.Thr408Met        Association with Parkinson disease     Han et al. ([2016](#mgg3527-bib-0014){ref-type="ref"})
  *GBA*      c.222_224delTAC       p.Thr75del         Pathogenic                             Koprivica et al. ([2000](#mgg3527-bib-0017){ref-type="ref"})
  *HEXA*     c.1274_1277dupTATC    p.Tyr427Ilefs\*5   Pathogenic                             Myerowitz and Costigan ([1988](#mgg3527-bib-0022){ref-type="ref"})
  *MAN2B1*   c.418C\>T             p.Arg140\*         Pathogenic                             Riise Stensland et al. ([2012](#mgg3527-bib-0025){ref-type="ref"})
  *CLN8*     c.374A\>G             p.Asn125Ser        Pathogenic                             Kousi et al., ([2012](#mgg3527-bib-0018){ref-type="ref"})
  *MANBA*    c.1922G\>A            p.Arg641His        Pathogenic                             Labauge et al. ([2009](#mgg3527-bib-0019){ref-type="ref"})
  *NEU1*     c.1004C\>A            p.Pro335Gln        Pathogenic                             Bonten ([2000](#mgg3527-bib-0006){ref-type="ref"})
  *ARSB*     c.1334C\>T            p.Pro445Leu        Pathogenic                             Kantaputra et al. ([2014](#mgg3527-bib-0016){ref-type="ref"})
  *SUMF1*    c.58C\>T              p.Leu20Phe         Pathogenic                             Cosma et al. ([2004](#mgg3527-bib-0008){ref-type="ref"})
  *NPC1*     c.3614C\>A            p.Thr1205Lys       Pathogenic                             Park et al. ([2003](#mgg3527-bib-0023){ref-type="ref"})
  *SMPD1*    c.1430C\>T            p.Pro477Leu        Pathogenic                             Simonaro, Desnick, McGovern, Wasserstein, and Schuchman ([2002](#mgg3527-bib-0028){ref-type="ref"})
  *SMPD1*    c.1460C\>T            p.Ala487Val        Pathogenic                             Simonaro et al. ([2002](#mgg3527-bib-0028){ref-type="ref"})
  *GNPTAB*   c.1931_1932delinsTG   p.Thr644Met        Pathogenic                             Velho et al., ([2015](#mgg3527-bib-0030){ref-type="ref"})
  *SGSH*     c.1159G\>A            p.Val387Met        VUS                                    NA
  *CTSC*     c.1319G\>A            p.Arg440Gln        VUS                                    NA
  *GNPTAB*   c.1818G\>A            p.Met606Ile        VUS                                    NA
  *CLN6*     c.923G\>C             p.Ser308Thr        VUS                                    NA
  *ARSB*     c.264G\>T             p.Gln88His         VUS                                    NA
  *CTNS*     c.319A\>C             p.Asn107His        VUS (+ no deletion detected)           NA
  *IDUA*     c.1345C\>A            p.His449Asn        VUS                                    NA
  *NEU1*     c.676G\>A             p.Asp226Asn        VUS                                    NA
  *AGA*      c.436T\>G             p.Leu146Val        VUS                                    NA

NA: not available; ?: unknown.
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###### 

Overview of the mutations detected in the 150 patients in whom a lysosomal storage disease was suspected

  Gene     Mutations                         Inheritance   Biochemically confirmed
  -------- --------------------------------- ------------- -------------------------
  CLN3     c.1222delT;c.1222delT             AR            
  CLN3     1,02 kb del;1,02 kb del           AR            
  CLN3     1,02 kb del;c.424delG             AR            
  CLN6     c.461_463delTCA;c.461_463delTCA   AR            
  CTNS     Del 57 kb;Del 57 kb               AR            
  GAA      c.2331+2T\>A;delE9                AR            Yes
  GBA      c.1448T\>C;c.1448T\>C             AR            Yes
  GLB1     c.367G\>A;c.817_818delinsCT       AR            
  GLB1     c.380G\>T;c.1369C\>T              AR            Yes
  GNPTAB   c.1196C\>T;c.3503_3504delTC       AR            Yes
  GNPTG    c.377G\>A;c.316G\>A               AR            
  HEXB     c.1082+5G\>A;c.1082+5G\>A         AR            Yes
  IDS      c.998C\>T (male patient)          XR            
  IDUA     c.1598C\>G;c.1598C\>G             AR            
  IDUA     c.46_57del;c.46_57del             AR            Yes
  LIPA     c.894G\>A;c.1024G\>A              AR            Yes
  MAN2B1   c.2248C\>T; c.2248C\>T            AR            Yes
  MFSD8    c.881C\>A;c.881C\>A               AR            
  MFSD8    c.77delT;c.77delT                 AR            
  NPC1     c.306T\>G;c.1691C\>A              AR            Yes
  NPC2     c.441+1G\>A;c.441+1G\>A           AR            Yes
  SGSH     c.220C\>T;?                       AR            Yes

All positive cases found in the panel analysis have been clinically confirmed and all samples which were subjected to biochemical analysis were found to be in the pathological range.

AR: autosomal recessive; XR: X‐linked recessive; ?: unknown.
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Below, we describe two cases with an unspecific phenotype where implementation of the gene panel resulted in a diagnosis: A patient with an initial suspicion of galactosialidosis (based on clinical signs and enzyme testing with borderline decreased beta‐galactosidase and absent neuraminidase activity) was found to have two pathogenic mutations in the *GNPTAB* gene, namely c.1196C\>T and c.3503_3504delTC, causing mucolipidosis II/III, while no mutations in *CTSA* were present. *GNPTAB*codes for the alpha and beta subunit of the GlcNAc‐1‐phosphotransferase enzyme which catalyzes the first step of the mannose‐6‐phosphate (M6P) tagging of lysosomal enzymes, allowing these to bind to the M6P receptor present on the trans‐Golgi network (Ghosh, Dahms, & Kornfeld, [2003](#mgg3527-bib-0013){ref-type="ref"}; Qian et al., [2015](#mgg3527-bib-0024){ref-type="ref"}). This interaction leads to the correct targeting of the enzymes to the lysosomes. As a result, patients affected with mucolipidosis II/III display a reduced activity of multiple enzymes. For instance, mucolipidosis type III is often referred to as pseudo‐Hurler polydystrophy (Coutinho, Prata, & Alves, [2012](#mgg3527-bib-0009){ref-type="ref"}).A consanguineous couple presented at consultation with their two children, a 7‐year‐old boy and an 8‐year‐old girl, both displaying a neurodegenerative disease course after having obtained normal developmental motoric and verbal milestones. At the age of 5 years, cognitive stagnation was followed by regression in both. The girl developed refractory epileptic seizures at the age of six and myoclonic periods of absence at the age of seven. The boy started to display periods of absence at the age of 6.5 years. The two sibs were furthermore affected by cerebellar atrophy, retinal abnormalities on electroretinograms, and showed signs of dysmetria. Initial genetic analysis for mitochondria‐related diseases did not show any pathogenic alterations. However, LSD panel analysis revealed the two children were homozygous for the c.77delT, p.Leu26Ter mutation in the *MFSD8* gene (alternatively *CLN7*), causing neuronal ceroid lipofuscinosis type 7. Segregation was confirmed in both parents, who were heterozygous. The neuronal ceroid lipofuscinoses are a group of diseases caused by mutations in 13 genes (*CLN1‐8*, *CLN10‐14*) and display an overlapping disease spectrum. For instance, recent proteomics analysis has revealed that one of the proteins which is markedly downregulated in neuronal ceroid lipofuscinosis type 7, is, besides MFSD8 itself, *CLN5* (Danyukova et al., [2018](#mgg3527-bib-0010){ref-type="ref"}). Moreover, while for instance the *CLN1*,*CLN2,*and *CLN10* genes encode for proteins with an enzymatic activity, this has currently not been demonstrated for *CLN3* and *MFSD8*, which give rise to endosomal/lysosomal transmembrane proteins, consequently making the development of biochemical assays for these latter two challenging (Mohammed, O\'Hare, Warley, Tear, & Tuxworth, [2017](#mgg3527-bib-0021){ref-type="ref"}). Here, gene panel screening proves to be a valuable alternative strategy.

4. DISCUSSION {#mgg3527-sec-0014}
=============

Prior to the usage of NGS, our lab performed standard biochemical analysis based on 4MU‐labeled substrates for the detection of LSDs. In total, biochemical tests were implemented in the clinic for 21 different LSDs (Table [2](#mgg3527-tbl-0002){ref-type="table"}). During an evaluation period of 30 months (1,069 samples), a diagnostic yield of 4.58% was attained for this approach. The NGS methodology used here, results in a diagnostic yield of 15%. This increase in yield goes hand in hand with the fact that 51 genes are now being investigated in comparison to the 21 enzymes which were tested previously. This implies that, although the absolute yield has more than tripled, a less strong improvement is seen in relative terms. For instance, when looking to the gene panel results of the LSDs which are in our biochemical testing list, a yield of 9/150% or 6% could be observed, which is slightly higher, but comparable to the 4.58% of the biochemical tests. This indeed indicates that the increase in yield of the gene panel is mainly due to the additional LSDs which were added to the panel. However, we also detected several patients with a carriership status of certain genes, implying that the real diagnostic success rate could be higher due to the fact that deletions at the gene level cannot be detected. In these cases, biochemical testing is appropriate. The diagnostic yield of gene panels varies strongly according to the type of the disease for which the panel is offered. For instance, while the yield for a congenital glycosylation disorders gene panel was found to be 14.8% (Jones et al., [2013](#mgg3527-bib-0015){ref-type="ref"}), this can be as much as 32% for a hypertrophic cardiomyopathy panel (Alfares et al., [2015](#mgg3527-bib-0001){ref-type="ref"}). This indicates that the disease nature plays a major role: the clinical presentation of hypertrophic cardiomyopathy is for instance expected to be more clear than when dealing with patients with a suspicion of lysosomal storage diseases who generally present with a more aspecific phenotype. In view of this, one could argument for the implementation of whole‐exome sequencing which has been shown to obtain yields between 25% and 50% (Xue, Ankala, Wilcox, & Hegde, [2015](#mgg3527-bib-0031){ref-type="ref"}). However, while the cost of whole‐exome sequencing is rapidly decreasing, trio‐analysis is advisable, and the data analysis is still more extensive than that of dedicated gene panels. Furthermore, it is expected to detect more unsolicited findings and variants of uncertain significance.

Interestingly, we could not observe a difference in diagnostic yield between children and adolescents on the one hand and adult patients on the other hand. This could imply that, despite an often more severe presentation of the phenotype in younger patients, the more aspecific nature of the disease at these ages potentially introduces a negative bias in terms of success rate. Conversely, patients in whom a late‐onset phenotype might present with a more specific phenotype, resulting in a better patient selection prior to LSD panel testing.

Taken together, we here demonstrate that the NGS‐based approach for the detection of LSDs is a valuable alternative next to the well‐established biochemical assays. The fact that a broader spectrum of diseases can be monitored in one single test significantly shortens the analysis time in complex cases and in cases where a biochemical test cannot be offered. Moreover, the genetic information is readily available, allowing familial segregation analysis. However, in case of a positive finding, biochemical testing still should be performed. This is especially the case when only a single mutation is detected or only variants of uncertain significance are observed in a particular gene. The gene panel can in these cases guide laboratories toward performing a specific biochemical test leading to a correct diagnosis.

In view of the possibility of detecting VUS and/or secondary findings, reporting of the results should be done carefully and should always be coupled to the clinical phenotype of the patient. For instance, when a pathogenic mutation is found in a gene which is not related to the clinical symptoms of the patient, the (probable) non‐causality of this mutation should be made clear in the report and the decision to report should always be in accordance with the informed consent papers signed by the patient. Nevertheless, reporting of this noncausal mutation could be worthwhile in terms of further familial testing.

The larger repertoire of diseases that can be interrogated by use of NGS panel testing mostly benefits patients in whom symptoms are not fully specific for a certain LSD. However, it has to be taken into account that large genomic deletions cannot be detected and that this gap should be filled in for genes where common deletions have been readily reported. In our case, we implemented a deletion test for *CTNS*, *CLN3, GAA,* and *GALC*. Furthermore, when dealing with clinical symptoms which are classical for a particular LSD, running a targeted biochemical test might be more appropriate, since NGS analysis will most likely require more resources.

We here thus show that NGS gene panel testing is a valuable alternative in comparison to the already established biochemical testing. By implementing the panel, we were able to broaden our disease spectrum and as such increased the absolute diagnostic yield. Furthermore, this methodology allows us to detect carriership status, allowing for further family testing and counseling. Taken together, we suggest to implement panel testing in the standard flow of LSD diagnostics.
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